NOVN Kisqali incumbent competitor Ibrance shows no OS benefit

ASCO2022 saw the eventual presentation of Pfizer's PALOMA-2 study, where, as we highlighted in our February 2020 Foveal report NOVN “Kisqali's kiss of life”, Ibrance failed to demonstrate any overall survival benefit in first line postmenopausal advanced breast cancer